Healthcare / Healthcare PlansNasdaqGS
$3.92
-0.06 (-1.51%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-69.0M · quality 42.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.1B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-27.7%
↓Gross Margin
18.5%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
+26.8%
FCF CAGR
—
FCF margin
-3.6%
FCF / Net income
0.81x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.92B · net income $-85.5M · FCF $-69.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $1.92B | $1.92B | $1.37B | $1.26B | $1.10B | $1.47B | $672.9M | $462.3M |
| Net Income | $-85.5M | $-85.5M | $-43.0M | $-213.4M | $-339.6M | $-587.8M | $-136.4M | $-363.7M |
| EBITDA | $-83.9M | $-83.9M | $-44.9M | $-207.6M | $-252.0M | $-636.8M | $-92.9M | $-186.1M |
| EPS | -0.17 | -0.17 | -0.08 | -0.44 | -0.71 | -1.42 | -1.54 | -4.14 |
| Gross Margin | 18.5% | 18.5% | 26.6% | 20.3% | 9.4% | -5.4% | — | — |
| Operating Margin | -4.4% | -4.4% | -3.3% | -14.2% | -26.1% | -43.3% | -13.8% | -39.6% |
| Net Margin | -4.4% | -4.4% | -3.1% | -16.9% | -31.0% | -39.9% | -20.3% | -78.7% |
| Balance Sheet | ||||||||
| Debt/Equity | — | — | — | 0.02 | 0.02 | 0.04 | -0.17 | — |
| Current Ratio | 1.33 | 1.33 | — | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $-69.0M | $-69.0M | $33.3M | $-145.2M | $-208.4M | $-283.0M | $-119.2M | $-159.9M |
| Returns | ||||||||
| ROE | -27.7% | -27.7% | -12.6% | -74.5% | -95.1% | -109.8% | 22.1% | 2063053.7% |
| Valuation | ||||||||
| P/B | 6.50 | 6.50 | 4.73 | 1.60 | 1.35 | — | — | — |
| Growth & Yield | ||||||||
| Revenue Growth | 40.3% | 40.3% | 8.8% | 15.0% | — | 118.8% | 45.6% | — |
| EPS Growth | -112.5% | -112.5% | 81.9% | 37.8% | — | 7.8% | 62.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+24.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.08 → -0.17
Residual
+24.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.